Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is Yarrow Bioscience (YARW) Stock Up +6.12% Today?

Why Is Yarrow Bioscience (YARW) Stock Up +6.12% Today?

Key Takeaways

  • Yarrow Bioscience (YARW) shares gained $0.87, or 6.12%, to $15.08 in midday trading, against a prior close of $14.21.
  • No press release, SEC filing, clinical update, or financing announcement was issued before the move, so the advance has no verified same-day catalyst.
  • The rebound follows a 22.74% single-session slide on Nov. 16 that pushed the stock toward the low end of its 52-week range of $12.39 to $46.95.
  • Fundamentals remain cash-backed but pre-revenue: $268.9 million in cash as of Sept. 30, a runway the company says extends into 2030, and a net loss of $9.7 million last quarter.
  • Sell-side coverage has broadened, with Jefferies initiating at Buy and a $40 target on Nov. 16, yet ratings alone have not halted the recent selling.
  • The gain is ordinary for this stock: average absolute daily move over the past 60 sessions was 5.1%, and 17 sessions produced moves as large or larger.
  • News Significance Score: 13/100 — no verified catalyst behind a move barely larger than this micro-cap's routine 5.1% daily swing.
  • Investors can review Price Targets, Earnings, and Forecast pages for deeper detail on the clinical-stage story.
  • For live, strategy-level signals across thousands of tickers, explore Trending AI Robots.

Yarrow Bioscience Shares Climb 6% in Midday Trading

Yarrow Bioscience, Inc. (YARW) is a Nasdaq-listed, clinical-stage biotechnology company developing therapies for autoimmune thyroid disease. Its lead asset, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR), designed as a potentially first-in-class subcutaneous treatment for Graves' disease and thyroid eye disease. The company was formed in July 2026 when VYNE Therapeutics merged with Yarrow Bioscience, and it employs a staff of just seven while running a Phase 2a/2b program.

Shares rose 6.12%, or $0.87, to $15.08 in midday trading, up from a prior close of $14.21, confirming an upward move. The stock traded between roughly $13.53 and $15.19 during the session. No company-specific announcement was identified ahead of the advance, and the price action is best characterized as an unconfirmed rebound rather than a news-driven re-rating.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found for the session. With no filing, data readout, partnership, or financing on the tape, the most consistent explanation is technical: shares were recovering part of the 22.74% collapse they suffered on Nov. 16, a drop that occurred even as new bullish coverage landed. That decline left the stock pressing against the $13.50 area, which has now held as support twice in two weeks — intraday lows of $13.53 on Nov. 17 and $13.53 again today, following the $12.39 floor hit in early November.

Liquidity is the second part of the story. Yarrow trades with a float of only a few million shares and a market capitalization near $140 million, so modest order flow can move the quote several percentage points. Turnover on the day was running below the stock's average daily volume of roughly 167,000 shares, meaning the advance was driven by thin supply rather than heavy accumulation. A short-covering bounce after a violent two-day selloff is plausible in that setting; a durable change in fundamentals is not evidenced by the data.

Market Context and Trading Activity

Volume was light relative to the recent norm, a signature of micro-cap drift rather than institutional conviction. Over the past 60 sessions the stock's average absolute daily change was about 5.1%, and six of those sessions produced double-digit moves, including an 18.8% decline on Nov. 4, a 16.6% rally on Nov. 11, and the 22.7% slide on Nov. 16. Today's 6.12% gain is therefore roughly 1.2 times the stock's typical swing — unremarkable against its own history.

The move appeared idiosyncratic rather than sector-driven. There was no broad biotech catalyst or index-level event tied to the timing, and the company's own news flow is quiet. The stock remains far below its 52-week high of $46.95, down roughly 65% from its August level near $40, and about 42% below the $26 per-share price of its roughly $172.5 million September equity offering. That offering overhang helps explain why rallies have struggled to hold. The Nov. 2 close of $17.93 and the Nov. 12 close of $19.63 mark the nearest overhead reference points.

News Significance Score

The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news and a rare, extreme price move. Yarrow's reading is 13 out of 100.

On the news side, there was no verifiable development on the day; the nearest items — third-quarter results on Nov. 12 and the Jefferies initiation on Nov. 16 — are routine for a company of this size and did not accompany today's buying. On the price side, the 6.12% advance was only about 1.2 times the 5.1% average daily move of the past 60 sessions, and 17 of those sessions produced equal or larger swings. Weak news and an unexceptional move combine into a low score.

What Comes Next for YARW

Attention turns to the fourth-quarter and full-year 2026 results, expected in early March, when investors will watch the burn rate against the $268.9 million cash balance and any update on enrollment in the DIRECTION-GD Phase 2a cohort. The decisive event remains Phase 2a topline data for YB-101 in Graves' disease, guided for the second half of 2027, alongside multiple-ascending-dose data from partner GenSci's China program.

The analyst consensus stands at Strong Buy across five covering firms, with expectations centered on trial execution rather than near-term revenue — the company has no product sales. Key risks include clinical disappointment, further dilution or resale pressure tied to the September offering, the binary nature of a single-asset pipeline, and the liquidity risk inherent in a thinly traded, sub-$150 million company with a small share count.

Trending AI Robots

Tickeron's Trending AI Robots page is a curated view of automated trading strategies that are performing best under current market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and this section surfaces only those showing the strongest results right now. The bots differ widely in approach, holding period, risk profile, performance metrics, and the symbols they trade, so a review of the leaderboard can help traders compare methodologies side by side. Explore the page to see which strategies are currently in favor.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: YARW

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


YARW in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 04, 2026

YARW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 2 of 2 cases where YARW's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on YARW as a result. In 2 of 4 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.

Following a +3.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where YARW advanced for three days, in 10 of 13 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where YARW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for YARW entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.967) is normal, around the industry mean (3.596). P/E Ratio (0.000) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (2.630) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. YARW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YARW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
251 Little Falls Drive
Phone
N/A
Employees
4
Web
https://www.yarrowbioscience.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.